Celltrion gains additional recognition in Europe with Ramshima SC

기타

by 세오냥코 2020. 7. 27. 22:57

The company aims to develop and produce various therapeutic proteins such as anti-cancer drugs based on biotechnology and animal cell mass culture technology.

It has the largest 140,000L animal cell culture protein drug production facility in Asia, and plans to establish a new plant in 3 considering future development schedule and demand.

The world's first developed biosimilar “Rimshima” for the treatment of autoimmune diseases was approved for sale by the US FDA in 2016.

2020/08/02 - [KOSPI] - HDC Hyundai Industry Development entered into Asiana Airlines due diligence and acquisition review

2020/07/30 - [KOSPI] - Woori Financial Group to support 10 trillion won in Korean New Deal

2020/07/27 - [KOSPI] - The future of Doosan Solus with hydrogen fuel cell source technology

저작자표시

'기타' 카테고리의 다른 글

Kakao with payment function that exceeds the age of 70s and 80s (0)	2020.07.28
Hanwha Systems Leads Korean Defense with Situational Awareness Camera (0)	2020.07.28
Corona Vaccine SK Chemicals is getting more attention with Bill Gates letter (0)	2020.07.28
The future of Doosan Solus with hydrogen fuel cell source technology (0)	2020.07.27
SK Biofarm writes a new history at the competition (0)	2020.07.26